Accordingly, Baha et al. highlighted that the administration of progesterone for 10 weeks in ovariectomized diabetic mice improves the different outcomes of diabetic nephropathy, reducing glomerulosclerosis and profibrotic/angiogenetic factors (TGF-β, vascular endothelial growth factor -A, type 1 receptor of angiotensin II), downregulating podocyte markers such as nephrin and podocin [168]. This evidence concerns the gene TGFB1 and diabetic kidney disease.